MIT Engineers Pace Hearts With 8-Month Ultrasound Patch After 1 Gene Shot
Updated
Updated · ZME Science · Jun 4
MIT Engineers Pace Hearts With 8-Month Ultrasound Patch After 1 Gene Shot
3 articles · Updated · ZME Science · Jun 4
Summary
A stamp-sized MIT ultrasound patch restored steady heart rhythms without surgery after a single gene-therapy injection made cardiac cells responsive to sound.
MscL-G22S ion channels inserted into heart tissue opened under targeted ultrasound, triggering calcium influx and contractions; engineered human heart cells followed the pulses, while unmodified cells did not.
In live rats with arrhythmias, the wearable patch regulated hearts during daily activity for more than eight months, and the team also demonstrated the approach on larger pig hearts.
The work targets a market where about 1 million pacemakers are implanted each year, offering a potential alternative to devices that require chest surgery and can cause infection, bleeding and hardware degradation.
Published in Nature Biomedical Engineering, the study is a step toward closed-loop wearable systems that could both image the heart and automatically correct rhythm misfires.
On June 3, 2026, a groundbreaking noninvasive pacemaker system was unveiled, promising to revolutionize heart rhythm regulation by eliminating the need for traditional surgical implants. The core innovation is a wearable ultrasound patch designed to precisely control heart activity without invasive procedures. This system was developed through a collaborative effort led by MIT engineers and researchers from several prominent institutions. USC researchers played a key role in designing the ultrasound transducer and advancing sonogenetics, while MIT contributed a specialized bioadhesive hydrogel that helps the patch adhere securely to the skin, enabling effective and comfortable heart rhythm management.